Home › Funds › BAKER BROS. ADVISORS LP › STOK

BAKER BROS. ADVISORS LP position in STOK

STOKE THERAPEUTICS INC · Health Care

BAKER BROS. ADVISORS LP reported holding 3,336,697 shares of STOK (STOKE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$109.2M, representing 0.57% of its reported portfolio and ranking #24 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed STOK holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)3.34M sh
Reported value held$109.18M
Portfolio Weight0.57%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BAKER BROS. ADVISORS LP's STOK position evolved

BAKER BROS. ADVISORS LP first disclosed a stake in STOK in Q3 2023 at 1,485,915 shares (US$5.9M). The position peaked in Q2 2026 at 3,336,697 shares, worth US$109.2M. Across 12 filings, BAKER BROS. ADVISORS LP increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 3,336,697 shares valued at US$109.2M. Notable position changes include a 37% increase in Q4 2023 (shares rose 157% over the following quarter), a 66% increase in Q1 2024 (shares were roughly flat over the following quarter), a 30% increase in Q2 2024 (shares fell 9% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.49M $5.85M New
Q4 2023 2.03M $10.68M Add
Q1 2024 3.37M $45.47M Add
Q2 2024 4.37M $59.02M Add
Q3 2024 4.37M $53.69M Hold
Q4 2024 4.63M $51.11M Add
Q1 2025 4.63M $30.82M Hold
Q2 2025 4.63M $52.59M Hold
Q3 2025 4.63M $108.90M Hold
Q4 2025 3.34M $105.91M Reduce
Q1 2026 3.34M $108.64M Hold
Q2 2026 3.34M $109.18M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About STOK and 13F data

STOK (STOKE THERAPEUTICS INC) is a Health Care company. 52 other funds we track also report a position in STOK — the largest reported positions include RTW INVESTMENTS, LP (US$184.0M), Lynx1 Capital Management LP (US$132.1M), Redmile Group, LLC (US$129.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding STOK

All STOK fund holders →

FAQ

How long has BAKER BROS. ADVISORS LP held STOK?

BAKER BROS. ADVISORS LP has disclosed STOK holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is BAKER BROS. ADVISORS LP's current position in STOK?

As of Q2 2026, BAKER BROS. ADVISORS LP holds 3.34M shares of STOK (STOKE THERAPEUTICS INC), valued at $109.18M, representing 0.57% of its reported portfolio and ranking #24.

Has BAKER BROS. ADVISORS LP been buying or selling STOK?

In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in STOK. The position peaked in Q2 2026 at 3.34M shares.

Which other funds hold STOK?

Other major institutional holders of STOK include RTW INVESTMENTS, LP, Lynx1 Capital Management LP, Redmile Group, LLC, among 52 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.